| 1 |
Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues[J]. Gastroenterology,2009,137(5):1593-1608.
|
| 2 |
Rhee SY, Margeridon-Thermet S, Nguyen M H, et al. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery[J]. Antiviral Res,2010,88(3):269-275.
|
| 3 |
Gao S, Duan ZP, Coffin CS. Clinical relevance of hepatitis B virus variants[J]. World J Hepatol,2015,7(8):1086-1096.
|
| 4 |
李晓东，蒋丽红，李梵, 等. 乙型肝炎病毒发生rtA181T突变的临床特点与意义分析[J]. 中华肝脏病杂志,2015,23(1):23-27.
|
| 5 |
姬粉芝，王磊，杨保华, 等. rtA181位点突变乙型肝炎病毒感染患者的临床特点及个体化再治疗效果[J]. 中华肝脏病杂志,2012,20(4):280-284.
|
| 6 |
Jiang SW, Yao LP, Hu AR, et al. Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates[J]. World J Gastroenterol,2014,20(45):17100-17106.
|
| 7 |
刘海霞，李娟，朱跃科, 等. 核苷类似物抗病毒治疗失败的慢性乙型肝炎患者基因型耐药分析[J]. 临床荟萃,2011,26(16):1385-1387.
|
| 8 |
恩替卡韦临床应用专家委员会. 恩替卡韦临床应用专家共识: 2015年更新[J]. 临床肝胆病杂志,2016,32(1):32-39.
|
| 9 |
刘晓彦，徐纯琼，张栩, 等. 未进行抗病毒治疗慢性乙型肝炎81例预存耐药分析[J]. 临床荟萃,2013,28(8):887-888.
|
| 10 |
Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure[J]. J Hepatol,2008,48(5):747-755.
|
| 11 |
Qi X, Xiong S, Yang H, et al. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents[J]. Antivir Ther,2007,12(3):355-362.
|
| 12 |
Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus[J]. J Clin Virol,2002,25(2):97-106.
|
| 13 |
Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy[J]. Antivir Ther,2010,15(3):471-475.
|
| 14 |
Ahn SH, Park YK, Park ES, et al. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene[J]. J Virol,2014,88(12):6805-6818.
|
| 15 |
Zhou LY, Chen EQ, Wang ML, et al. Biological characteristics comparison of HBV rtA181T mutants with truncated or substituted HBsAg expression in vitro and in vivo model systems[J]. Sci Rep,2016,6:39260.
|
| 16 |
Rodriguez C, Chevaliez S, Bensadoun P, et al. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing[J]. Hepatology,2013,58(3):890-901.
|
| 17 |
Yuen LK, Ayres A, Littlejohn M, et al. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B[J]. Antiviral Res,2007,75(1):64-74.
|
| 18 |
Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound[J]. Hepatology,2008,48(1):88-98.
|
| 19 |
李新艳，尹有宽，张继明, 等. 阿德福韦耐药乙型肝炎病毒毒株生物学特性的研究[J]. 中华传染病杂志,2009(8):478-483.
|
| 20 |
Dai J, Chen EQ, Bai L, et al. Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model[J]. Virol J,2012,9:280.
|
| 21 |
王江华，李俊强，蒋栋, 等. 乙型肝炎病毒rtA181V/T和rtN236T变异ADV耐药株表达质粒的构建及其病毒学特征[J]. 中华检验医学杂志,2007,30(9):1035-1039.
|
| 22 |
Gaia S, Barbon V, Smedile A, et al. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine[J]. J Hepatol,2008,48(4):540-547.
|
| 23 |
杨松，邢卉春，王琦, 等. 慢性乙型肝炎患者阿德福韦酯治疗出现病毒学突破的耐药分析[J/CD]. 中华实验和临床感染病杂志(电子版),2014,8(3):94-97.
|
| 24 |
Kekule AS, Lauer U, Meyer M, et al. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator[J]. Nature,1990,343(6257):457-461.
|
| 25 |
Lauer U, Weiss L, Hofschneider PH, et al. The hepatitis B virus pre-S/S(t) transactivator is generated by 3’ truncations within a defined region of the S gene[J]. J Virol,1992,66(9):5284-5289.
|
| 26 |
Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant[J]. Antivir Ther,2008,13(7):875-879.
|
| 27 |
Lai MW, Huang SF, Hsu CW, et al. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy[J]. Antivir Ther,2009,14(2):249-261.
|
| 28 |
Yeh CT, Chen T, Hsu CW, et al. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B[J]. BMC cancer,2011,11:398.
|